BioSpace News Archive

Centene Corporation (NYSE: CNC) today issued a reminder that it will provide its consolidated 2020 annual guidance, including WellCare Health Plans, Inc. (WellCare), after the close of trading on Tuesday, March 3, 2020, and host a conference call on Wednesday, March 4, 2020 at approximately 8:30 a.m. (Eastern Time)

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it has completed the first closing under a recently executed Securities Purchase Agreement with Innoviva, Inc.

Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today that the company has achieved over 65% subject enrollment in its ongoing phase 3 clinical trial investigating emixustat hydrochloride (“emixustat”) in patients with macular atrophy secondary to Stargardt disease.

Less Than 500 Blister Packs Remain From Initial Production Run of More Than 8,700 Blister Packs NEW YORK, NY, Feb. 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that it has commenced its 2 nd productio

New training model helps build strong and healthy relationships for children and caregivers

LAVAL, Quebec, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today announced that it will host a conference call at 1:00 PM Eastern Time on Friday, February 14, 2020 to discuss the Company’s financial results for the third

SAN DIEGO, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it plans to release its fourth quarter and year-end 2019 financial results before the market opens on Thursday, February 27, 2020 and hold a conference call at 8:30 AM Eastern Time (5:30 AM Pacific Time) to discuss the Company’s financial resu

VANCOUVER, British Columbia, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company is pleased to announce it is undertaking a non-brokered private placement of up to CDN $1,200,000 or approximately 14.1M units (the “Units”) at a price of $0.085 per Unit. Each Unit is comprised of one Class A common share (a “Share”) and one Share purchase warrant. Each whol

SARASOTA, Fla. , Feb. 13, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: IVOB) , a medical device company focused on treating infertility with its FDA-cleared INVOcell® product, today announced the appointment of Inger Britt Carlsson , PhD, as the Company’s Vice President of Medical Affairs. Dr. Carlsson will be developing and overseeing INVO Bioscience’s educational sym

Ceribell, Inc. announced the results of a study, led by Dr. Brandon Westover, a leading expert in the field of electroencephalography (EEG) and brain monitoring at Massachusetts General Hospital, Harvard Medical School, that confirms reduced array EEG systems like the one used by the Ceribell Rapid Response EEG System, meet the gold standard for detection of seizures